Wang X, Liu W, Zhan C, Zhang Y, Li X, Wang Y
iScience. 2025; 28(1):111626.
PMID: 39850359
PMC: 11754826.
DOI: 10.1016/j.isci.2024.111626.
Lai Y, Han X, Xie B, Xu Y, Yang Z, Wang D
Cancer Sci. 2024; 115(7):2220-2234.
PMID: 38623968
PMC: 11247551.
DOI: 10.1111/cas.16186.
Ju J, Zhang H, Guan S, Liu C, Du J, Shen X
Molecules. 2023; 28(24).
PMID: 38138487
PMC: 10745707.
DOI: 10.3390/molecules28247997.
Amin M, El-Far Y, El-Mowafy M, Elgaml A
Clin Epigenetics. 2023; 15(1):180.
PMID: 37941056
PMC: 10634085.
DOI: 10.1186/s13148-023-01593-8.
Rialdi A, Duffy M, Scopton A, Fonseca F, Zhao J, Schwarz M
Nat Cancer. 2023; 4(8):1157-1175.
PMID: 37537299
PMC: 10948969.
DOI: 10.1038/s43018-023-00609-9.
EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies.
Wang B, Liu Y, Liao Z, Wu H, Zhang B, Zhang L
Exp Hematol Oncol. 2023; 12(1):52.
PMID: 37268997
PMC: 10236851.
DOI: 10.1186/s40164-023-00405-2.
Combating castration-resistant prostate cancer by co-targeting the epigenetic regulators EZH2 and HDAC.
Schade A, Kuzmickas R, Rodriguez C, Mattioli K, Enos M, Gardner A
PLoS Biol. 2023; 21(4):e3002038.
PMID: 37104245
PMC: 10138213.
DOI: 10.1371/journal.pbio.3002038.
Distinct binding pattern of EZH2 and JARID2 on RNAs and DNAs in hepatocellular carcinoma development.
Wen Z, He K, Zhan M, Li Y, Liu F, He X
Front Oncol. 2022; 12:904633.
PMID: 36578923
PMC: 9792092.
DOI: 10.3389/fonc.2022.904633.
Cri du chat syndrome patients have DNA methylation changes in genes linked to symptoms of the disease.
Holland P, Wildhagen M, Istre M, Reiakvam O, Dahl J, Soraas A
Clin Epigenetics. 2022; 14(1):128.
PMID: 36242045
PMC: 9563797.
DOI: 10.1186/s13148-022-01350-3.
as a potential prognostic and therapeutic biomarker by affecting tumor development and immune microenvironment in hepatocellular carcinoma.
Tan Z, Chen M, Peng F, Yang P, Peng Z, Zhang Z
Transl Cancer Res. 2022; 11(8):2713-2732.
PMID: 36093522
PMC: 9459514.
DOI: 10.21037/tcr-22-218.
Integrating the Epigenome and Transcriptome of Hepatocellular Carcinoma to Identify Systematic Enhancer Aberrations and Establish an Aberrant Enhancer-Related Prognostic Signature.
Huang P, Zhang B, Zhao J, Li M
Front Cell Dev Biol. 2022; 10:827657.
PMID: 35300417
PMC: 8921559.
DOI: 10.3389/fcell.2022.827657.
New Insights on the Nuclear Functions and Targeting of FAK in Cancer.
Pomella S, Cassandri M, Braghini M, Marampon F, Alisi A, Rota R
Int J Mol Sci. 2022; 23(4).
PMID: 35216114
PMC: 8874710.
DOI: 10.3390/ijms23041998.
A Novel Expression Signature from the Perspective of Mesenchymal-Epithelial Transition for Hepatocellular Carcinoma with Regard to Prognosis, Clinicopathological Features, Immune Cell Infiltration, Chemotherapeutic Efficacy, and Immunosuppressive....
Xu L, Zheng Q
J Oncol. 2021; 2021:5033416.
PMID: 34367283
PMC: 8342179.
DOI: 10.1155/2021/5033416.
LINC01348 suppresses hepatocellular carcinoma metastasis through inhibition of SF3B3-mediated EZH2 pre-mRNA splicing.
Lin Y, Wu M, Liu Y, Lyu P, Yeh C, Lin K
Oncogene. 2021; 40(28):4675-4685.
PMID: 34140643
DOI: 10.1038/s41388-021-01905-3.
EZH2-miRNA Positive Feedback Promotes Tumor Growth in Ovarian Cancer.
Liu T, Cai J, Cai J, Wang Z, Cai L
Front Oncol. 2021; 10:608393.
PMID: 33718109
PMC: 7947696.
DOI: 10.3389/fonc.2020.608393.
Focal Adhesion Kinase (FAK) Over-Expression and Prognostic Implication in Pediatric Hepatocellular Carcinoma.
Francalanci P, Giovannoni I, De Stefanis C, Romito I, Grimaldi C, Castellano A
Int J Mol Sci. 2020; 21(16).
PMID: 32806748
PMC: 7460809.
DOI: 10.3390/ijms21165795.
linc00174-EZH2-ZNF24/Runx1-VEGFA Regulatory Mechanism Modulates Post-burn Wound Healing.
Huang M, Huang X, Jiang B, Zhang P, Guo L, Cui X
Mol Ther Nucleic Acids. 2020; 21:824-836.
PMID: 32805486
PMC: 7452087.
DOI: 10.1016/j.omtn.2020.07.010.
Sex-biased genetic programs in liver metabolism and liver fibrosis are controlled by EZH1 and EZH2.
Lau-Corona D, Bae W, Hennighausen L, Waxman D
PLoS Genet. 2020; 16(5):e1008796.
PMID: 32428001
PMC: 7263639.
DOI: 10.1371/journal.pgen.1008796.
Long noncoding RNA metastasis-associated lung adenocarcinoma transcript 1 cooperates with enhancer of zeste homolog 2 to promote hepatocellular carcinoma development by modulating the microRNA-22/Snail family transcriptional repressor 1 axis.
Chen S, Wang G, Tao K, Cai K, Wu K, Ye L
Cancer Sci. 2020; 111(5):1582-1595.
PMID: 32129914
PMC: 7226208.
DOI: 10.1111/cas.14372.
MicroRNAs Involved in Metastasis of Hepatocellular Carcinoma: Target Candidates, Functionality and Efficacy in Animal Models and Prognostic Relevance.
Weidle U, Schmid D, Birzele F, Brinkmann U
Cancer Genomics Proteomics. 2019; 17(1):1-21.
PMID: 31882547
PMC: 6937123.
DOI: 10.21873/cgp.20163.